Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

Hacioglu, Muhammet; Kostek, Osman; Karabulut, Senem; Tastekin, Didem; SEZGİN GÖKSU, SEMA; Alandag, Celal; Akagunduz, Baran; Bilgetekin, Irem; Caner, Burcu; ŞAHİN, AHMET; Yildiz, Birol; Kose, Fatih; Kaplan, Muhammet; Gulmez, Ahmet; Dogan, Ender; Guven, Deniz; Gurbuz, Mustafa; Ergun, Yakup; KARAAĞAÇ, MUSTAFA; Demiray, Atike; Turker, Sema; Sakalar, Teoman; Ozkul, Ozlem; Telli, Tugba; Sahin, Suleyman; KILIÇKAP, SAADETTİN; Bilici, Ahmet; ERDOĞAN, BÜLENT; ÇİÇİN, İRFAN

Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

Atıf İçin Kopyala

Hacioglu M. B., Kostek O., Karabulut S., Tastekin D., SEZGİN GÖKSU S., Alandag C., ...Daha Fazla

JOURNAL OF BUON, cilt.25, sa.4, ss.1897-1903, 2020 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 25 Sayı: 4
Basım Tarihi: 2020
Dergi Adı: JOURNAL OF BUON
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
Sayfa Sayıları: ss.1897-1903
Anahtar Kelimeler: hepatocellular carcinoma, regorafenib, disease control rate, overall survival, chemotherapy, anti-VEGF therapy, SORAFENIB, CANCER
Akdeniz Üniversitesi Adresli: Evet

Özet

Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the secondor third-line setting.